<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1788">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05137886</url>
  </required_header>
  <id_info>
    <org_study_id>IIT2021051-EC-1</org_study_id>
    <nct_id>NCT05137886</nct_id>
  </id_info>
  <brief_title>PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma</brief_title>
  <official_title>PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Hematology &amp; Blood Diseases Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Hematology &amp; Blood Diseases Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Young patients with relapsed or refractory classic Hodgkin's lymphoma will be treated with&#xD;
      PD-1 inhibitor combined with decitabine as second-line salvage treatment for four cycles. If&#xD;
      PR or CR was obtained after salvage treatment, patients will receive GBM conditioning regimen&#xD;
      followed by ASCT as consolidation therapy. High-risk R/R cHL patients will be treated with&#xD;
      PD-1 inhibitor after ASCT for 1 year. The purpose of current study is to determine the&#xD;
      clinical efficacy and safety of PD-1 inhibitor combined with decitabine followed by ASCT as&#xD;
      second-line treatment in patients with relapsed or refractory classic Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>PFS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>2 years</time_frame>
    <description>ORR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response rate</measure>
    <time_frame>2 years</time_frame>
    <description>CRR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>2 years</time_frame>
    <description>DOR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival rate</measure>
    <time_frame>2 years</time_frame>
    <description>OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of the adverse events</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">47</enrollment>
  <condition>Hodgkin Lymphoma, Adult</condition>
  <condition>Relapse</condition>
  <condition>Refractory Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>PD-1 inhibitor combined with decitabine followed by ASCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive salvage treatment of PD-1 inhibitor Tislelizumab combined with decitabine for four cycles, If PR or CR was obtained after salvage treatment, patients will receive GBM (gemcitabine, bulsufan and melphalan) conditioning regimen followed by ASCT. High-risk patients will receive PD-1 inhibitor for 1 year after ASCT as maintenance therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD-1 inhibitor</intervention_name>
    <description>decitabine 10mg on d1-5, Tislelizumab 200mg on d8，21 days as one cycle.</description>
    <arm_group_label>PD-1 inhibitor combined with decitabine followed by ASCT</arm_group_label>
    <other_name>decitabine</other_name>
    <other_name>autologous stem cell transplantation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects must have histological confirmation of relapsed or refractory classic Hodgkin&#xD;
             lymphoma (HL).&#xD;
&#xD;
          2. 18 to 65 years of age.&#xD;
&#xD;
          3. Subjects with lymphoma must have at least one measureable lesion &gt;1 cm as defined by&#xD;
             lymphoma response criteria.&#xD;
&#xD;
          4. Proper functioning of the major organs: 1) The absolute value of neutrophils&#xD;
             (≥1×10^9/L); 2) platelet count (≥75×10^9/L); 3) Serum creatinine &lt;1.5 times Upper&#xD;
             Limit Normal (ULN) ; 4) Serum total bilirubin &lt; 1.5 times ULN; 5) Aspartate&#xD;
             Aminotransferase (AST), Alanine Aminotransferase (ALT) ≤3 times ULN; 6) Serum&#xD;
             creatinine (Cr) ≤2 ULN, or glomerular filtration rate ≥40ml/min; 7) Thyrotropin (TSH)&#xD;
             or free thyroxine (FT4) or free triiodothyronine (FT3) were all within the normal&#xD;
             range (±10%).&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) Performance status 0-2.&#xD;
&#xD;
          6. LVEF value measured by echocardiography ≥50%.&#xD;
&#xD;
          7. Life expectancy &gt; 3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with central nervous system involvement by lymphoma.&#xD;
&#xD;
          2. Patients with active autoimmune diseases requiring systematic treatment in the past&#xD;
             two years (hormone replacement therapy is not considered systematic treatment, such as&#xD;
             type I diabetes mellitus, hypothyroidism requiring only thyroxine replacement therapy,&#xD;
             adrenocortical dysfunction or pituitary dysfunction requiring only physiological doses&#xD;
             of glucocorticoid replacement therapy); Patients with autoimmune diseases who do not&#xD;
             require systematic treatment within two years can be enrolled.&#xD;
&#xD;
          3. Known systemic vasculitides, primary or secondary immunodeficiency(such as HIV&#xD;
             infection or severe inflammatory disease).&#xD;
&#xD;
          4. Pregnant or breastfeeding women.&#xD;
&#xD;
          5. Major surgery within 4 weeks before enrollment.&#xD;
&#xD;
          6. Impaired cardiac function:Ejection fraction &lt;50% on MUGA scan. QTc interval &gt; 450msecs&#xD;
             on baseline ECG. Myocardial infarction within 6 months prior to starting study; other&#xD;
             clinically significant heart disease (e.g. unstable angina, congestive heart failure&#xD;
             or uncontrolled hypertension, uncontrolled arrhythmias).&#xD;
&#xD;
          7. Other concurrent severe and/or uncontrolled medical conditions: Patients with another&#xD;
             primary malignant disease, except those that do not currently require treatment; acute&#xD;
             or chronic liver, pancreatic or severe renal disease; another severe and/or&#xD;
             life-threatening medical disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dehui Zou, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Hematology &amp; Blood Diseases Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dehui Zou, Dr.</last_name>
    <phone>86-022-23909282</phone>
    <email>zoudehui@ihcams.ac.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Huimin Liu, Dr</last_name>
    <phone>86-022-23909282</phone>
    <email>liuhuimin@ihcams.ac.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institute of Hematology &amp; Blood Diseases Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dehui Zou, Dr.</last_name>
      <phone>86-022-23909282</phone>
      <email>zoudehui@ihcams.ac.cn</email>
    </contact>
    <contact_backup>
      <last_name>Huimin Liu, Dr.</last_name>
      <phone>86-022-23909282</phone>
      <email>liuhuimin@ihcams.ac.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 16, 2021</study_first_submitted>
  <study_first_submitted_qc>November 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute of Hematology &amp; Blood Diseases Hospital</investigator_affiliation>
    <investigator_full_name>Zou Dehui</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>Hodgkin lymphoma</keyword>
  <keyword>relapse</keyword>
  <keyword>refractory</keyword>
  <keyword>autologous stem cell transplantation</keyword>
  <keyword>PD-1 inhibitor</keyword>
  <keyword>decitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Immune Checkpoint Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

